Back to News
Market Impact: 0.35

Morgan Stanley cuts Zscaler stock price target on competition concerns

Analyst InsightsCorporate EarningsCorporate Guidance & OutlookCompany FundamentalsCybersecurity & Data PrivacyAntitrust & Competition
Morgan Stanley cuts Zscaler stock price target on competition concerns

Morgan Stanley cut Zscaler’s price target to $145 from $155 and reiterated an Equalweight rating, citing weakening forward guidance, slower new-logo acquisition, and rising competition from Palo Alto Networks, Netskope, and Cato Networks. The firm sees no material turnaround until new SecOps traction, improved sales leadership, and better operating structure emerge, none of which are expected in the next few quarters. Against that cautious backdrop, Zscaler still beat fiscal Q3 2026 expectations with EPS of $1.08 versus $1.01 consensus and revenue of $850.48 million versus $835.55 million.

Analysis

This is less about one company miss and more about a marginal change in the competitive map of secure access/SASE. The market is likely to keep punishing vendors where pricing power is visibly slipping because the category is still consolidating and buyers can now force harder comparisons across platform breadth, not just point-product performance. That dynamic is most dangerous for the second-tier players: when the large suites improve bundle economics, standalone vendors can see deal elongation and smaller initial land sizes even if headline growth still screens as healthy. The key second-order effect is that weakness at ZS can spill over to the rest of the security software basket if investors start assuming AI-era consolidation will compress standalone security multiples across the board. That said, the competitive beneficiary is not necessarily the most visible pure-play rival; it is the broader platform vendors that can cross-subsidize security inside larger workflows and use procurement leverage to win in the 2,000–10,000 seat band. If that segment is softening, the conversion cycle likely worsens over the next 2-3 quarters before any new product launch can matter. The timeline matters: there is a near-term earnings-risk window of weeks to months, but the real catalyst gap is 6-12 months because the supposed turnaround levers are still in rollout mode. In the meantime, any quarter where bookings, net new logos, or operating leverage fail to inflect will keep the multiple capped, regardless of reported EPS beats. The contrarian risk is that the stock may already be discounting the competitive thesis too aggressively if execution stabilizes and the market starts valuing ZS as a high-margin cash compounder rather than a growth reacceleration story. For Morgan Stanley specifically, this reads like a broader caution on secular names where the valuation is no longer protected by growth scarcity. The better setup may be relative shorts in names facing the same competitive issue but with weaker margin structure or more dependence on new-logo growth. If the market wants confirmation, the safest tell will be whether peers with larger platform footprints continue taking share without needing a dramatic price concession.